The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.

Tag:

Pfizer

Latest Headlines

Latest Headlines

NIH backs pharma giants and academics' projects to revive R&D castoffs

The NIH has advanced an ongoing effort to give castoffs from drug pipelines a new lease on development, committing $12.7 million to fund 9 collaborations between academic and pharma groups to find new treatments in areas of unmet need such as Alzheimer's disease, Duchenne muscular dystrophy and schizophrenia.

GutCheck nabs $4M, aids Pfizer with consumer-research software

Denver-based market research startup GutCheck has found $4 million for a Series B round of financing.

Synexus wins Pfizer's favor for South African trials

Patient-recruitment specialist Synexus has won a place in Pfizer's stable of preferred providers, giving the company advance information about future clinical trials and a leg up on other outsourcers.

Conatus Pharma aims for $69M IPO to fund liver-disease drug

Conatus Pharmaceuticals has joined a long line of drug developers seeking to go public. The San Diego-based company, which has a lead drug candidate acquired from Pfizer, revealed plans on Friday to complete an initial public offering of up to $69 million.

Pfizer gets shot at reversing contentious Alabama court ruling

It is Pfizer that will get another chance to knock down an Alabama Supreme Court ruling on the safety of generic drugs, but it stands in for the entire drug development industry that wants to see the the ruling reversed.

Pfizer's potential stars Eliquis, Xeljanz see sluggish sales

Pfizer believes it has a winner with Eliquis. It has the right market niche, a replacement for blood thinner warfarin, and the clinical data that should make it a star. What it hasn't had so far is a fast start toward bigtime sales.

Credit Suisse says Pfizer patent win will discourage 'at-risk' launches

Will Pfizer's big patent win against Teva Pharmaceutical Industries and India's Sun Pharma on Protonix discourage more "at-risk" drug launches of generics in the U.S.?

AARP fears Pfizer tactics to defend Lipitor could become model

A new AARP study worries that Pfizer's aggressive use of price hikes, pay-for-delay deals, and discounts and coupons when Lipitor faced generic competition will become the blueprint for the industry.

Teva loses $2B gamble on generic of Pfizer's Protonix

When Teva Pharmaceutical Industries launched a generic version of Protonix in 2007 before its patent expiration, it set aside $670 million to compensate Pfizer for lost profits on the drug. But with a settlement announced today, the company is finding itself $1.6 billion short.

Pfizer turns to upstart CytomX for $635M deal on armed antibody tech

Pfizer is partnering up with South San Francisco-based CytomX Therapeutics on a discovery program, putting the biotech's R&D platform to work on finding some next-gen antibody-drug conjugates for cancer targets.